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Recent target validation studies have shown that inhibition of the protein interaction between annexin
A2 and the S100A10 protein may have potential therapeutic beneﬁts in cancer. Virtual screening identi-
ﬁed certain 3,4,5-trisubstituted 4H-1,2,4-triazoles as moderately potent inhibitors of this interaction. A
series of analogues were synthesized based on the 1,2,4-triazole scaffold and were evaluated for inhibi-
tion of the annexin A2–S100A10 protein interaction in competitive binding assays. 2-[(5-{[(4,6-Dimeth-
ylpyrimidin-2-yl)sulfanyl]methyl}-4-(furan-2-ylmethyl)-4H-1,2,4-triazol-3-yl)sulfanyl]-N-[4-(propan-2-
yl)phenyl]acetamide (36) showed improved potency and was shown to disrupt the native complex
between annexin A2 and S100A10.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Small molecule drug discovery has largely focused on drug tar-
gets within a fairly limited set of families of enzymes and receptors
that offer tractable pharmacological space. Proteomics research
has opened up a new, potentially very rich, target area consisting
of the interacting faces of protein partners. Recent studies have
provided evidence that protein–protein interactions could offer
scope for small molecule intervention. For example, the interaction
between Mdm2 and p53, and the interaction between Bcl2 and Bak
have both been explored pharmacologically using small molecule
inhibitors, which have subsequently shown promise as therapeutic
agents.1–3 It is of interest that both p53 and Bak contain a short
helical sequence that docks into a well-deﬁned groove-like feature
on the surface of the respective binding partners, which in both
cases constitutes a small globular protein. This suggests that some
protein interactions, characterised by these features, may be
manipulated using small molecules.
S100 proteins constitute a family of small globular adaptor pro-
teins that regulate cell functions by virtue of their capacity to inter-
act with protein binding partners.4,5 Annexins are important
binding partners of S100 proteins5 and they contain a short helical
sequence feature at the N-terminus that allows binding to severalmembers of the S100 family. The S100A10 protein and annexin A2
(AnxA2) form a classic pairing in this way.6 The interaction
between these proteins is very well characterised and shows sim-
ilarities with the tractable protein interactions described above, in
that a small helix docks into a deep well-deﬁned binding crevice.7,8
Both S100A10 and AnxA2 have been implicated in cell matrix inva-
sion, cell movement and cell adhesion and as such play important
roles in the regulation of therapeutically relevant processes such as
vascular neo-angiogenesis and tumour cell metastastis.9–12
Using receptor-guided random docking approaches and bio-
chemical screening, we have previously identiﬁed several clusters
of small molecule inhibitors of this protein interaction.13 Here we
describe the optimization of a cluster of substituted 1,2,4 triazole
compounds emanating from this docking strategy to achieve inhib-
itors with improved potency.2. Results and discussion
2.1. Structure-based screening
We have previously reported the in silico screening of 0.7 mil-
lion compounds using the AnxA2 binding pocket of S100A10 as a
receptor.13 Following detailed analysis of the binding poses, and
biochemical assessment of the ability of the top scoring com-
pounds to inhibit the interaction between S100A10 and the AnxA2
N-terminus, 29 potential inhibitory compounds were identiﬁed,
which were distributed over 10 different clusters. A cluster of four
Figure 1. Chemical structures and IC50 values of the active compounds 1a–d identiﬁed through virtual screening.13
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that appeared to relate to their chemical structure (1a–d; Fig. 1).
This was of interest since we have previously used ligand-guided
screening methods to identify similar 1,2,4-triazoles as moderately
potent inhibitors of this protein interaction.14 Analysis of the bind-
ing mode of 1a, predicted using the GOLD programme15 (Fig. 2b),
suggested that it lies across the binding groove occupied by the
cognate AnxA2 N-terminus (Fig. 2a), thereby inhibiting access of
the latter. Compound 1a interacts mainly with hydrophobic areas
of this binding groove (identiﬁed as H1 and H2 in Fig. 2b). The ori-
entation of the substituted phenyl moiety in compound 1a is gov-
erned by hydrophobic CH–p stacking interactions mediated by
Met12 in the hydrophobic region H1. Both Phe86 and Phe13 are
also predicted to contribute to the binding of this group, through
hydrophobic and van der Waals interactions (Fig. 3a). The lower
potency of the compounds with more polar heterocyclic systems
at the position of this phenyl moiety (Fig. 1, 1b–d) is compatible
with the hypothesis that a hydrophobic binding region accommo-
dates this ring system. The 1,2,4-triazole core of 1a is positioned at
the centre of the AnxA2 binding groove, whereas the furfuryl sub-
stituent at the triazole N4-position is located towards the H2
region and is predicted to make hydrophobic interactions with
Leu78, Phe38 and Phe41 (Fig. 3b). From this binding mode analysis
it appears that the two hydrophobic regions H1 and H2 play a
dominant role in the inhibitory potency of compound 1a. The
potency of 1a (IC50 = 37 lM) was low compared that of the cognate
AnxA2(1–14) peptide ligand (IC50 = 1.2 lM), but similar to that
previously observed for related 1,2,4-triazoles, which lacked the
acetamide-linked aromatic ring system.14 Here we have investi-
gated structure–activity relationships of this series of compounds,
focusing in particular on the contribution of this aromatic system
to inhibition of the protein interaction with the aim of gaining
improvements in the potency of these compounds.
2.2. Chemical synthesis
Compounds 1a, 27–56. The substituted ethyl acetate 3
(Scheme 1) was prepared by reacting 4,6-dimethyl-pyrimidine-2-
thiol 2 with bromoethyl acetate in the presence of sodium acetate
as a base in ethanol. Subsequent reaction of ester 3 with excess
hydrazine monohydrate yielded acyl hydrazide 4. Condensation
of the latter with various substituted aromatic or aliphatic isothio-
cyanates 5 in ethanol, followed by base-catalysed cyclization,
resulted in the formation of substituted 1,2,4-triazoles (6–10).
Chloro-N-aryl-acetamides 13–26 were prepared by reacting
substituted aryl amines 11 with 2-chloroactyl or propionyl chlo-
rides 12 in the presence of Et3N as a base.
Analogues of 1a were synthesized using a 12-well Radley’s par-
allel synthesizer. 3-Mercapto-1,2,4-triazole derivatives 6–10 weretreated with chloro-N-aryl-acetamide derivatives 13–26 in the
presence of inorganic base in DMF to afford the desired compounds
27–56 (Scheme 1) in moderate to good yields.16–22
Compounds 62–66. Condensation of the acetohydrazide 57
(Scheme 2) with aromatic or aliphatic isothiocyanates 5 in ethanol
followed by base-catalysed cyclization afforded the required
substituted 3-mercapto-5-methyl-1,2,4-triazoles 58–60. Finally,
the target 5-methyl-1,2,4-triazoles 62–66 were prepared by react-
ing substituted 3-mercapto-5-methyl-1,2,4-triazoles 58–60 with
chloro-N-aryl-acetamides 61 in the presence of potassium carbon-
ate as a base in DMF.23–33
2.3. Structure–activity relationships (SARs)
2.3.1. Nature of the acetamide-linked ring system
Taking compound 1a as starting point, we replaced the substi-
tuted phenyl ring side chain with an aliphatic amide side chain
to yield 27. The reduction in potency associated with this modiﬁ-
cation suggested the importance of the phenyl ring for binding
(see Fig. 4 for typical IC50 curves). Replacement of the substituted
phenyl ring with the aromatic but more polar thiazole (28)
resulted in lower inhibitory activity comparable to what was
observed above for compound 1b. Introduction of a methyl substi-
tuent onto the thiazole reversed the potency drop (29). A similar
pattern was observed for the related, methyl-substituted isoxazole
ring at this position (30). The lower potency of 28 can be explained
by postulating that binding mainly relies on hydrophobic interac-
tions, in keeping with the predicted model in which the phenyl
group of 1a occupies the hydrophobic H1 region of the AnxA2
binding groove (Figs. 2b and 3a). We therefore investigated if intro-
duction of alternative hydrophobic substituents into the ring sys-
tem would result in better interactions (Table 1).
2.3.2. Acetamide-linked phenyl ring substitutions
An unsubstituted phenyl ring (31) was not associated with a
reduction in potency, however, repositioning the two methyl sub-
stituents on the phenyl group increased potency, suggesting that
the substitution pattern is in fact important. Compared to an
unsubstituted ring (31), introduction of a single methyl group at
either the 3- or 4-position was associated with a small increase
in potency (32 and 33). The 2,4-dimethyl substituted analogue
34 displayed similar potency, while the 3,4-dimethyl substitution
in 35 resulted in a moderate increase in potency. Analysis of the
predicted binding mode of compound 35 (Fig. 2b) suggested that
the orientation of the 3,4-dimethylphenyl moiety is governed by
hydrophobic interactions and causes a change in the location of
the 4,6-dimethylpyrimidine moiety, which differs from that
observed for compound 1a (Fig. 2b) in that it is ﬂipped away into
a more hydrophilic region. As a result it is involved in more polar
Figure 2. (a) Binding mode of the AnxA2 N-terminal peptide (represented as sticks;
C: grey, N: blue, O: red) within the binding pocket on S100A10 (molecular surface C:
green, N: blue, O: red, S: yellow, H: white). Hydrophobic regions of the binding
pocket (H1 and H2) are shown. The white rectangle represents the area of the
binding pocket used to visualise the docked poses in panels b and c. (b) Predicted
binding modes of compounds 1a (C: magenta, N: dark blue, O: red, S: yellow, lone
pairs: dark grey), 35 (C: light blue), and 36 (C: light grey). Hydrogens have been
removed. (c) Predicted binding modes of compounds 48 (C: green), 52 (C: bright
yellow, F: light blue), and 43 (C: light grey). Methyl moiety on OMe groups projects
downwards and is obscured in the ﬁgure. Figure created in Pymol (DeLano).
Figure 3. Hydrophobic residues in the S100A10 dimer (represented as sticks C:
green, N: blue, O: red, S: yellow, H: white) creating binding areas H1 (a) and H2 (b)
for the substituted phenyl ring (a) and pendant furfuryl ring (b) of compounds 1a,
35 and 36. Compounds are coloured as in Figure 2b. Figure created in Pymol
(DeLano).
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phobic isopropyl substitution at the para-position of the phenyl
ring (36) yielded a compound with an IC50 value of 4 lM, whichis almost 10-fold greater than the initial hit compound 1a and
comparable to that of the cognate peptidic ligand (IC50 = 1 lM).
This is highly reminiscent of the SAR observed for a distinct series
of inhibitors of this target we identiﬁed previously.13 A predicted
docking solution of 36 (Fig. 2b) suggested that this compound
had a similar binding pose as 1a, with the para-isopropyl group
projecting towards the H1 pocket likely to be the main reason for
its improved activity. We also tested the effect of hydrophobic
electron-withdrawing substitutions on the phenyl ring. Although
a CF3 substitution at the para position (37) did not provide any
advantage over the unsubstituted ring system in terms of potency,
the 3,5-di-CF3 analogue 38was comparatively potent. Introduction
of a para-chloro phenyl substituent (39) did not result in higher
potency, however, the para-bromo derivative 40 was 5-fold more
potent than compound 1a.
2.3.3. Triazole N4 substituents
We next turned our attention to N4 substituents (R1) of the
1,2,4-triazole scaffold (Table 2). For compound 35, the furfuryl
substituent at this position is predicted to project towards the
hydrophobic region H2 (Fig. 3b). The speciﬁc relevance of the
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Scheme 1. Synthetic route for 3,4,5-tri-substituted 1,2,4-triazoles. Reagents and conditions: (a) bromoethyl acetate, NaOAc in EtOH, reﬂux for 1 h; (b) NH2–NH2H2O, reﬂux
overnight; (c) (i) EtOH, reﬂux overnight; (ii) 1 M aq NaOH, 45 C, 45 min then 10% aq HCl; (d) CH2Cl2, Et3N, RT, overnight; (e) K2CO3, DMF, 45 C, overnight, then H2O.
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Figure 4. Inhibition of the interaction between the AnxA2 N-terminus and S100A10
by Non-labelled AnxA2(Ac1–14) peptide (s) or compounds 36 (N), 40 (d), and 49
(h).
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were investigated. Substitution of the furfuryl moiety of compound
35 with a hydrophobic allyl substituent retaining p electroniccharacteristics (41), a mixed aliphatic and polar (3-methoxypro-
pyl) substituent (42), or an aromatic polar (4-methoxyphenyl) sub-
stituent (43) and aromatic chloro (4-chlorophenyl) substituent
(44), all resulted in a reduction of potency, suggesting that the fur-
furyl group possessed a speciﬁc combination of geometric and
chemical properties relevant to support binding. Using compound
35 as the starting point, extension of the sulfanyl side chain by
addition of a methylene group (45) did not appear to be advanta-
geous in terms of activity and was not explored further.
Following the substitution patterns of the most potent com-
pound (36) in our series, we combined the 4-(isopropyl)phenyl
substitution with allyl (46), 3-methoxypropyl (47), 4-methoxy-
phenyl (48) and 4-chlorophenyl (49) at the triazole N4 position.
The resulting isopropyl derivatives were all somewhat less active
than 36 itself but were each individually more potent than the cor-
responding compound from the 3,4-dimethyl series that was based
on compound 35. Thus in the context of hydrophobic electron-
donating substitutions at the phenyl ring, of the groups tested,
the N4 furfuryl group appeared to be optimal.
Table 1
SARs of 2-[5-(4,6-dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-substituted (R)-acetamide analogues (1a–d and 27–40). Data
are based upon 12 observations
NN
N S
SN
N
O
H
N
O
R2
R3
R4
R5
NN
N S
H
NS
O
O
N
N
R
III
Compd Type R2 R3 R4 R5 R pIC50 ± SE IC50 (lM)
Peptide 5.92 ± 0.04 1.2
*1a I Me H H Me 4.42 ± 0.08 37
*1b 4.28 ± 0.06 53
*1c 3.96 ± 0.14 108
*1d 3.98 ± 0.10 103
27 II — — — — H 3.75 ± 0.15 178
28 II — — — — Thiazol-2-yl 3.89 ± 0.06 129
29 II — — — — 4-Me-thiazol-2-yl 4.53 ± 0.06 30
30 II — — — — 5-Me-isoxazol-3-yl 4.37 ± 0.07 43
31 I H H H H — 4.63 ± 0.04 23
32 I H Me H H — 4.89 ± 0.04 13
33 I H H Me H — 4.96 ± 0.04 11
34 I Me H Me H — 4.83 ± 0.04 15
35 I H Me Me H — 5.02 ± 0.04 10
36 I H H iPr H — 5.35 ± 0.04 4
37 I H H CF3 H — 4.55 ± 0.07 28
38 I H CF3 H CF3 — 5.05 ± 0.03 9
39 I H H Cl H — 4.76 ± 0.03 17
40 I H H Br H — 5.14 ± 0.03 7
* Compounds 1a–d were purchased from Asinex.
Table 2
SARs of 3,4,5-trisubstituted-1,2,4-triazole analogues (35–37 and 41–56). Data are
based upon 12 observations
NN
N S
R1
S
H
N
O
N
N
n R2
Compd n R2 R1 pIC50 ± SE IC50 (lM)
35 1 3,4-Dimethyl Furfuryl 5.02 ± 0.04 10
41 1 3,4-Dimethyl Allyl 4.56 ± 0.03 27
42 1 3,4-Dimethyl 3-OMe-propyl 4.49 ± 0.04 32
43 1 3,4-Dimethyl 4-OMe-phenyl 4.29 ± 0.09 52
44 1 3,4-Dimethyl 4-Cl-phenyl 4.23 ± 0.08 59
45 2 3,4-Dimethyl Furfuryl 4.62 ± 0.03 24
36 1 4-iPr Furfuryl 5.35 ± 0.04 4
46 1 4-iPr Allyl 5.01 ± 0.03 10
47 1 4-iPr 3-OMe-propyl 5.13 ± 0.04 7
48 1 4-iPr 4-OMe-phenyl 4.82 ± 0.02 15
49 1 4-iPr 4-Cl-phenyl 4.58 ± 0.04 27
37 1 4-CF3 Furfuryl 4.55 ± 0.07 28
50 1 4-CF3 Allyl 5.08 ± 0.04 8
51 1 4-CF3 3-OMe-propyl 5.02 ± 0.04 10
52 1 4-CF3 4-OMe-phenyl 5.35 ± 0.04 4
53 1 4-CF3 4-Cl-phenyl 5.07 ± 0.03 8
54 1 3,5-Di-CF3 4-OMe-phenyl 5.14 ± 0.04 7
55 1 4-Cl 4-OMe-phenyl 4.65 ± 0.05 22
56 1 4-MeO 4-OMe-phenyl 3.81 ± 0.03 154
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for compound 37, which contains a CF3 moiety at the para-position
of the phenyl ring. Allyl (50), 3-methocypropyl (51), 4-methoxy-
phenyl (52) and 4-chlorophenyl (53) substitutions resulted in
increased potency compared to 37. The methoxyphenyl derivative
52 was the most potent compound in this group and is 10-fold
more potent than the starting compound 1a. It was also morepotent than the triazole-N4-substituted 4-methoxyphenyl deriva-
tives containing electron-donating isopropyl (48) or 3,4-dimethyl
(43) groups on the acetamide-linked phenyl ring. Alternative
replacements at this phenyl ring did not improve the potency
achieved with that of compound 52. The 3,5-diCF3 phenyl deriva-
tive 54 was equipotent with 52 while the 4-chlorophenyl deriva-
tive 55 and the 4-methoxy derivative 56 were less potent. Weak
resonance donating properties of the halogen may be relevant in
this context, as could be the electron-donating properties of the
methoxy group. Overall, the 4-methoxyphenyl group at N4
appeared optimal for compounds that contained a hydrophobic
electron-withdrawing group at the phenyl ring, while substitutions
that increase ring electron density were not favoured in this
context.
Interestingly, docking studies of the N4 4-methoxyphenyl
derivatives (43, 48, 52 and 54–56) showed that most of the com-
pounds adopted an alternative binding pose compared to that of
the N4 furfuryl compounds (Fig. 2c). According to this binding
pose, compounds stretch across most of the binding area occupied
by the N-terminus of the cognate AnxA2 ligand (Fig. 2c). This bind-
ing pose could be due to the introduction of bulk (para-substituted
methoxyphenyl groups) at the N4-position of the triazole ring. The
4-methoxyphenyl substituent of the compounds appears to mimic
the interactions of the Val3 side chain of the AnxA2 peptide in the
crystal structure (Fig. 2a and c). The presence of AnxA2-Val3 is
essential for binding to S100A10 since its substitution leads to sub-
stantial loss of binding.34 In all these compounds, the 4,6-dimeth-
ylpyrimidine moiety extends into the hydrophilic region, similar to
what was predicted for compound 35 (Fig. 2b), whereas the para-
substituted phenyl moiety is involved in hydrophobic interactions
with the far end of the H1 binding pocket. In the case of compound
52 the para-CF3-phenyl moiety makes good van der Waals and
hydrophobic interactions (Fig. 2c), whereas the para-(isopro-
pyl)phenyl moiety of compound 48 (Fig. 2c) is involved in weaker
Table 3
SARs of 5-methyl-4-substituted (R2)-4H-[1,2,4]triazole analogues (62–66). Data are
based upon 12 observations
NN
N S
R1
H
N
O
n R2
Compd n R2 R1 pIC50 ± SE IC50 (lM)
62 1 3,4-Dimethyl Furfuryl 2.32 ± 0.48 >1000
63 2 3,4-Dimethyl Furfuryl 2.95 ± 0.26 >1000
64 1 4-iPr Furfuryl 4.40 ± 0.03 40
65 1 4-iPr Allyl 3.86 ± 0.11 138
66 1 4-iPr 3-OMe-propyl 3.79 ± 0.14 164
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tive 52. The low potency of compound 43 could not be justiﬁed
based on an alternative binding mode as the 3,4-dimethylphenyl
moiety appears to form good hydrophobic and van der Waals
interactions with the far end of the H1 binding pocket.
2.3.4. Sulfanyl side chain
Finally, we examined the importance of the 4,6-dimethylpyrim-
idin-2-ylsulfanyl side chain on inhibitory potency (Table 3).
Inspection of the predicted binding pose of compound 1a shows
that the side chain in question interacts with the comparatively
hydrophilic region of the binding pocket (Figs. 2b and 3a). Trunca-
tion of the 4,6-dimethylpyrimidin-2-ylsulfanyl side chain of com-
pound 35 to the corresponding methyl derivative 62 resulted in
complete loss of activity. Extending the side chain of compound
62 by an additional methylene group (63) also abolished activity.
Truncation of the 4,6-dimethylpyrimidin-2-ylsulfanyl side chain
of compound 36 to give the corresponding methyl derivative 64
resulted in a 10-fold loss of activity, whereas in the case of com-
pounds 46 and 47 similar truncation to methyl derivatives 65
and 66 resulted in 14- and 23-fold lower activity, respectively.
Thus the 4,6-dimethylpyrimidin-2-ylsulfanyl side chain makes an
important contribution to the inhibitory activity of these
compounds.
2.4. Inhibition of native complex
Although it is clear that the tri-substituted 1,2,4 triazoles act as
inhibitors of the binding of the N-terminus of AnxA2 to S100A10, it
is necessary to conﬁrm that the native complex of the two full-
length proteins, AnxA2 and S100A10, is also inhibited. InteractionFigure 5. Co-immunoprecipitation of AnxA2 with S100A10. S100A10 was immu-
noprecipitated from cell lysates and co-immunoprecipitation of AnxA2 was
assessed by Western blotting. The amount of AnxA2 in the S100A10 immunopre-
cipitate was quantiﬁed using Scion Image Software and expressed as a percentage
of the vehicle-treated sample (n = 4 ± SE). Inset shows a typical Western blot
labelled as follows: ref, total lysate reference indicating the AnxA2 position on the
gel; V, 36, P, immunoprecipitates of lysates preincubated with vehicle, compound
36 or AnxA2(1–14) peptide, respectively.between the native proteins can be measured by co-immunopre-
cipitation as shown in Figure 5 and previously.13 AnxA2 is detected
by Western blotting after immunoprecipitation of the S100A10
protein, suggesting that binding occurs between the two proteins.
In the presence of the isolated synthetic peptide AnxA2(1–14), the
amount of AnxA2 in the S100A10 immunoprecipitate is reduced,
due to it competing with the binding between native AnxA2 and
S100A10. In the presence of compound 36, the amount of AnxA2
in the immunoprecipitate is also reduced, indicating that it does
indeed inhibit the native complex.
3. Conclusions
Analysis of the molecular interactions of compound 1a shows
that the hydrophobic pockets H1 and H2 of the S100A10 receptor
play a crucial role in the afﬁnity of these compounds. Complex
interactions appear to occur between the N4- and the acetamide-
linked ring systems, such that dependent on the nature of the N4
substituent, the hydrophobic character and the electron density
on the acetamide-linked ring is correlated with inhibition patterns.
Additionally, the 4,6-dimethylpyrimidin-2-ylsulfanyl side chain
appears to be important for the activity, and this needs further
exploration.
Compounds 36 and 52 are the most potent in present com-
pound series with 10-fold increase in activity compared to the ini-
tial hit compound 1a. They also displayed higher activity than a set
of triazole analogues that lack an acetamide-linked ring that we
have reported on previously.14 Compounds 36 and 52, and various
analogues described here, could thus be used as probes further to
understand the molecular interactions between S100A10 and
AnxA2 and may also serve as potential starting point for further
optimization.4. Experimental
4.1. Protein structure preparation
SYBYL-X 1.0 biopolymer was used for the preparation of the
S100A10–AnxA2 N-terminal peptide complex (PDB ID: 1BT6).
The chain termini (Lys91, Pro1 and Ser11 of AnxA2) were charged.
Hydrogen atoms were added. AMBER 7 FF99 charges were assigned
to the complex. The side chain amides of Gln45 and Gln60 were re-
oriented to maximize hydrogen bonding. Powell’s energy minimi-
zation of the complex was achieved by a stepwise manner using
AMBER 7 FF99 parameters. Initial optimization was not performed,
energy gradient of 0.5 kcal/mol was maintained and a maximum of
5000 iterations were used. A centroid was deﬁned by a set of atoms
within 5 Å of the AnxA2 ligand peptide and the peptide was
extracted from the complex. Water molecules were deleted before
docking.
4.2. GOLD (v3.0.1) docking
Docking of each ligand was performed in 10 different genetic
algorithm (GA) runs, and for each of these a maximum number
of 100,000 GA operations were performed on a single population
of 100 individuals. Early termination of docking runs was allowed
if the top three solutions were within 1.5 Å RMSD of each other.
Crossover, mutation, migration (95, 95 and 10, respectively),
hydrogen bonding (4.0 Å), and van der Waals (2.5 Å) parameters
were set as default value throughout the docking. A binding site
radius of 12 Å was found to be optimal. Flipping was not allowed
for those ligands that have ring-NHR and ring-NHR1R2 groups in
order to avoid the addition of large torsional energy penalties to
the total ﬁtness scores.
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Assessment of compound activity was performed as
described.35 Brieﬂy, a Cy5-labelled S100A10 tracer was developed
and binding of a Cy3-labelled AnxA2(Ac1–14) peptide ligand was
assessed using a ﬂuorescence resonance energy transfer readout.
Assays were carried out in Nunc black non-treated 384-well plates
at 20 C in 50 lL buffer C. All incubations were performed in qua-
druplicate. Compounds, peptide and buffer controls were added to
the wells in a 10 lL volume in 5% DMSO. Cy5-labelled S100A10 tra-
cer (407 nM) and Cy3-labelled AnxA2(Ac1–14) peptide ligand
(1.33 lM) were pre-incubated for 5 min at 20 C and 40 lL of the
preformed complex was then added to the wells and mixed for
10 s to yield a ﬁnal DMSO concentration of 1%. After 5 min incuba-
tion at 20 C, readings were taken on a Perkin Elmer Envision plate
reader by excitation at 488 nm and emission at 695 nm. Fluores-
cence resonance energy transfer (FRET) was calculated by subtract-
ing the sum of the ﬂuorescence emission of S100A10-Cy5 and
AA2(1–14)-Cy3 individually from that measured for the co-incu-
bated partners. Compound binding was calculated as percentage
of non-treated control and data were analysed by non-linear
regression (dose response—variable slope with bottom and top
parameters ﬁxed at 0% and 100%, respectively) using Graphpad
Prism Software to determine the IC50 of binding (primary assay).
4.4. Immunoprecipitation assay
Human MDA-MB-231 breast cancer cells were extracted in
50 mM Tris–HCl (pH 8.0) buffer containing 150 mM sodium chlo-
ride and 1% (v/v) NP-40. Lysates were centrifuged at 17,000g
and incubated at 4 C for 16 h with 10 lL S100A10 antibody (BD
transduction Laboratories) and 50 lL protein A/G agarose (Alpha
Diagnostic International Inc). Protein A/G agarose was then recov-
ered by centrifugation at 2400g, washed three times with 10 mM
phosphate buffer (pH 7.4) containing 2.7 mM potassium chloride
and 137 mM sodium chloride, resuspended in 50 lL of 160 mM
Tris–HCl (pH 6.8) buffer containing 4% (w/v) sodium lauryl sulfate,
20% (v/v) glycerol, 0.04% (w/v) bromophenol blue and 10% (v/v) 2-
mercaptoethanol, boiled at 99 C for 10 min and centrifuged at
17,000g for 10 min. The supernatant was then analyzed by
SDS–PAGE after which the gel was transferred to a nitrocellulose
ﬁlter. The ﬁlter was incubated with an AnxA2 monoclonal antibody
(1:3000; BD Transduction Laboratories) followed by incubation
with an anti-mouse horseradish peroxidase IgG conjugate
(1:5000; GE Healthcare) and then developed using the ECL detec-
tion reagent (GE Healthcare).
4.5. Synthesis
All reagents were purchased directly from commercial sources
and were used as supplied, unless otherwise stated. Accurate mass
and nominal mass measurements were performed using a Waters
2795-Micromass LCT electrospray mass spectrometer. All NMR
spectra were recorded in deutero-DMSO in 5 mm tubes, with tri-
methylsilane as an internal standard, using a Bruker ACS-120
instrument at 400 MHz (1H NMR). Thin layer chromatography
was performed using aluminium-backed silica gel 60 plates
(0.20 mm layer), the ascending technique was used with a variety
of solvents. Visualization was by UV light at either 254 or 365 nm.
4.5.1. (4,6-Dimethyl-pyrimidin-2-ylsulfanyl)-acetic acid ethyl
ester (3)
To a solution of 2 (14.2 g, 100 mmol) in EtOH (190 mL) was
added NaOAc (12.3 g, 150 mmol) and ethyl bromoacetate
(11.3 mL, 100 mmol). The mixture was heated under reﬂux for
60 min and EtOH was then evaporated. The residue was dilutedwith H2O and extracted with EtOAc. The extract was dried over
Na2SO4, ﬁltered, and concentrated under vacuum to afford 3 as a
yellow oil (15.5 g, 69%). m/z (ES), found 227.0821 (C10H15N2O2S
[M+H]+) requires 227.2954; dH/ppm (400 MHz, d6-DMSO): 6.97
(1H, s, Ar-H), 4.10 (2H, q, J = 7.1, CH2), 3.94 (2H, s, CH2), 2.33 (6H,
s, 2CH3), 1.18 (3H, t, J = 7.1, CH3).
4.5.2. (4,6-Dimethyl-pyrimidin-2-ylsulfanyl)-acetic acid
hydrazide (4)
To a solution of 3 (12.3 g, 54.3 mmol) in EtOH (170 mL) was
added NH2NH2H2O (16.1 mL, 32 mmol) and the mixture was
heated under reﬂux overnight. The reaction was cooled and con-
centrated under vacuum. The pale white precipitate obtained
was washed with petroleum ether (PE)–EtOH (3:1) and then dried
under vacuum to afford 4 as a pale yellow powder (9.7 g, 84%).m/z
(ES), found 213.0846 (C8H13N4OS [M+H]+) requires 213.0732; dH/
ppm (400 MHz, d6-DMSO): 9.21 (1H, s, NH), 6.96 (1H, s, Ar-H),
4.17 (2H, br s, NH2), 3.79 (2H, s, CH2), 2.34 (6H, s, 2CH3).
4.5.3. 5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-furan-
2-ylmethyl-4H-[1,2,4]triazole-3-thiol (6)
To a solution of 4 (5.0 g, 23.6 mmol) in EtOH (175 mL) was
added furfuryl isothiocyanate (3.4 mL, 23.6 mmol) and the mixture
was heated under reﬂux overnight. The reaction was cooled and
concentrated under vacuum. The white precipitate obtained was
washed with PE–EtOH (1:1). To the suspension was added 2 M
aq NaOH (40 mL) and the mixture was heated under reﬂux for
3 h before cooling. The reaction was neutralized with 10% aq HCl
and was extracted with EtOAc. The organic layer was dried over
Na2SO4, ﬁltered, and concentrated. The resulting yellow solid was
recrystallized from EtOH to afford 6 as an off-white powder
(2.4 g, 30%). m/z (ES), found 332.0606 (C14H14N5OS2 [MH])
requires 332.0718; dH/ppm (400 MHz, d6-DMSO): 13.72 (1H, s,
NH of thione tautomer), 7.63 (1H, t, J = 1.3/1.4, Ar-H), 6.98 (1H, s,
Ar-H), 6.46–6.41 (2H, m, Ar-H), 5.37 (2H, s, CH2), 4.53 (2H, s,
CH2), 2.31 (6H, s, 2CH3).
4.5.4. 4-Allyl-5-(4,6-dimethyl-pyrimidin-2-ylsulfanylmethyl)-
4H-[1,2,4]triazole-3-thiol (7)
To a solution of 4 (4.5 g, 21.2 mmol) in EtOH (150 mL) was
added allyl isothiocyanate (2.2 mL, 21.2 mmol) and the reaction
mixture was heated under reﬂux overnight. It was cooled and
the white precipitate formed was collected by ﬁltration and was
washed with EtOH. To the suspension was added 1 M aq NaOH
(25 mL) and the mixture was heated at 45 C for 90 min before
cooling. The reaction was neutralized with 10% aq HCl. The yellow
precipitate formed was collected by ﬁltration, washed with H2O,
followed by EtOH, and then vacuum dried to afford 7 as a pale
white powder (2.9 g, 47%). m/z (ES), found 292.0616 (C12H14N5S2
[MH]) requires 292.0769; dH/ppm (400 MHz, d6-DMSO): 13.67
(1H, s, NH of thione tautomer), 7.00 (1H, s, Ar-H), 5.97–5.84 (1H,
m, CH), 5.21 [1H, dd, J = 1.2 + 10.4, N-CH2 (Ha)], 5.04 [1H, dd,
J = 1.2 + 17.2, N-CH2 (Hb)], 4.73 (2H, d, J = 5.1, @CH2), 4.45 (2H, s,
CH2), 2.34 (6H, s, 2CH3).
4.5.5. 5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(3-
methoxy-propyl)-4H-[1,2,4]triazole-3-thiol (8)
To a solution of 4 (4.5 g, 21.2 mmol) in EtOH (170 mL) was
added 3-methoxypropyl isothiocyanate (2.7 mL, 21.2 mmol) and
the mixture was heated under reﬂux overnight. The reaction was
cooled and concentrated under vacuum. To the yellow crystalline
solid thus formed was added 1 M aq NaOH (25 mL) and the mix-
ture was heated at 45 C for 120 min before cooling. The reaction
was neutralized with 10% aq HCl and was extracted with EtOAc.
The extract was dried over Na2SO4, ﬁltered, and concentrated.
The resulting yellow solid was washed with Et2O and recrystallized
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m/z (ES), found 324.0871 (C13H18N5OS2 [MH]) requires
324.1031; dH/ppm (400 MHz, d6-DMSO): 13.60 (1H, s, NH of thione
tautomer), 7.01 (1H, s, Ar-H), 4.51 (2H, s, CH2), 4.07 (2H, t, J = 7.3,
CH2OCH3), 3.34 (2H, t, J = 6.0, N-CH2), 3.22 (3H, s, OCH3), 2.35
(6H, s, 2CH3), 2.16–1.92 (2H, m, CH2).
4.5.6. 5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(4-
methoxy-phenyl)-4H-[1,2,4]triazole-3-thiol (9)
To a solution of 4 (4.5 g, 21.2 mmol) in EtOH (175 mL) was
added 4-methoxyphenyl isothiocyanate (3.0 mL, 21.2 mmol) and
the mixture was heated under reﬂux overnight. The reaction was
cooled and concentrated under vacuum. To the yellow powder
thus formed was added 1 M aq NaOH (50 mL) and the mixture
was heated under reﬂux for 60 min before cooling. The reaction
was neutralized with 10% aq HCl. The yellow precipitate formed
was collected by ﬁltration, was washed with EtOH–MeOH (1:1)
and then vacuum dried to afford 9 as a pale yellow powder
(5.9 g, 77%). m/z (ES), found 359.9088 (C16H18N5OS2 [M+H]+)
requires 360.0875; dH/ppm (400 MHz, d6-DMSO): 13.76 (1H, s,
NH of thione tautomer), 7.30 (2H, d, J = 9.0, Ar-H), 6.99 (2H, d,
J = 9.0, Ar-H), 6.93 (1H, s, Ar-H), 4.32 (2H, s, CH2), 3.78 (3H, s,
OCH3), 2.28 (6H, s, 2CH3).
4.5.7. 4-(4-Chloro-phenyl)-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazole-3-thiol (10)
To a solution of 4 (5.0 g, 23.6 mmol) in EtOH (175 mL) was
added 4-chlorophenyl isothiocyanate (4.0 g, 23.6 mmol). The mix-
ture was heated under reﬂux for 20 min and the formation of white
precipitate was observed. The reaction was cooled and the white
precipitate was collected by ﬁltration and was washed with EtOH.
To the precipitate was added 1 M aq NaOH (50 mL) and the mix-
ture was heated at 45 C for 45 min before cooling. The reaction
was neutralized with 10% aq HCl. The white precipitate formed
was collected by ﬁltration, washed with MeOH and then vacuum
dried to afford 10 as an off-white powder. In order to recover more
10 the ﬁltrate was extracted with EtOAc. The extract was dried
over Na2SO4, ﬁltered, and concentrated. The resulting pale white
powder was recrystallized fromMeOH to afford 10 as a white pow-
der. The combined yield of 10 was 4.9 g (57%). m/z (ES), found
363.8376 (C15H15ClN5S2 [M+H]+) requires 364.0379; dH/ppm
(400 MHz, d6-DMSO): 13.86 (1H, s, NH of thione tautomer), 7.52
(2H, d, J = 8.8, Ar-H), 7.43 (2H, d, J = 8.8, Ar-H), 6.93 (1H, s, Ar-H),
4.38 (2H, s, CH2), 2.28 (6H, s, 2CH3).
4.5.8. 2-Chloro-N-(3,4-dimethyl-phenyl)-acetamide (13)
To a solution of 3,4-dimethylaniline (1.85 g, 15 mmol) in CH2Cl2
(60 mL) was added Et3N (2.1 mL, 15.2 mmol) and the mixture was
allowed to stir at room temperature (RT) for 10 min. To this was
then added chloroacetyl chloride (1.19 mL, 15 mmol) and the reac-
tion was left to stir at RT for 4 h. The reaction was concentrated
under vacuum. The residue was diluted with H2O and extracted
with EtOAc. The extract was washed with 1 M aq HCl, dried over
Na2SO4, ﬁltered, and concentrated under vacuum. The yellow pre-
cipitate formed was washed with Et2O and then vacuum dried. to
afford 13 as a white powder (2.2 g, 74%). m/z (ES), found 198.0658
(C10H13ClNO [M+H]+) requires 198.0607; dH/ppm (400 MHz, d6-
DMSO): 10.11 (1H, s, NH), 7.35 (1H, s, Ar-H), 7.30 (1H, dd,
J = 1.8 + 8.1, Ar-H), 7.07 (1H, d, J = 8.1, Ar-H), 4.21 (2H, s, CH2),
2.19 (3H, s, CH3), 2.16 (3H, s, CH3).
4.5.9. 2-Chloro-N-phenyl-acetamide (14)
Procedure as for 13 except using aniline (1.37 mL, 15 mmol)
and the reaction mixture was allowed to stir at RT overnight. Pure
14 (without washing with Et2O) was obtained as off-white crystals
(963 mg, 38%). m/z (ES), found 170.0979 (C8H9ClNO [M+H]+)requires 170.0294; dH/ppm (400 MHz, d6-DMSO): 10.27 (1H, s,
NH), 7.58 (2H, dd, J = 1.0 + 8.5, Ar-H), 7.36–7.30 (2H, m, Ar-H),
7.12–7.06 (1H, m, Ar-H), 4.25 (2H, s, CH2).
4.5.10. 2-Chloro-N-m-tolyl-acetamide (15)
Procedure as for 14 except using m-toluidine (1.62 mL,
15 mmol) and the reaction mixture was allowed to stir at RT over-
night. Pure 15 was obtained as a brown powder (1.98 g, 72%). m/z
(ES), found 184.0486 (C9H11ClNO [M+H]+) requires 184.0451; dH/
ppm (400 MHz, d6-DMSO): 10.19 (1H, s, NH), 7.42 (1H, s, Ar-H),
7.37 (1H, d, J = 8.4, Ar-H), 7.20 (1H, t, J = 7.8, Ar-H), 6.90 (1H, d,
J = 7.5, Ar-H), 4.23 (2H, s, CH2), 2.28 (3H, s, CH3).
4.5.11. 2-Chloro-N-p-tolyl-acetamide (16)
Procedure as for 14 except using p-toluidine (1.61 g, 15 mmol)
and the reaction mixture was allowed to stir at RT overnight. Pure
16 was obtained as a brown powder (1.81 g, 66%). dH/ppm
(400 MHz, d6-DMSO): 10.18 (1H, s, NH), 7.47 (2H, d, J = 8.4, Ar-
H), 7.13 (2H, d, J = 8.2, Ar-H), 4.22 (2H, s, CH2), 2.25 (3H, s, CH3).
4.5.12. 2-Chloro-N-(2,5-dimethyl-phenyl)-acetamide (17)
Procedure as for 14 except using 2,5-dimethylaniline (1.87 mL,
15 mmol). The pale yellow precipitate formed was washed with
PE–CH2Cl2 (4:1) and then vacuum dried. Pure 17 was obtained as
a white powder (1.1 g, 37%).m/z (ES), found 198.1024 (C10H13ClNO
[M+H]+) requires 198.0607; dH/ppm (400 MHz, d6-DMSO): 9.57
(1H, s, NH), 7.20 (1H, s, Ar-H), 7.10 (1H, d, J = 7.7, Ar-H), 6.93
(1H, d, J = 7.6, Ar-H), 4.28 (2H, s, CH2), 2.25 (3H, s, CH3), 2.15 (3H,
s, CH3).
4.5.13. 2-Chloro-N-(2,4-dimethyl-phenyl)-acetamide (18)
To a solution of 2,4-dimethylaniline (1.87 mL, 15 mmol) in CH2-
Cl2 (60 mL) was added Et3N (2.1 mL, 15 mmol) and the mixture was
allowed to stir at RT for 10 min. To this was added chloroacetyl
chloride (1.19 mL, 15 mmol) and the reaction was left to stir at RT
for 4 h. The reaction was concentrated under vacuum. The residue
was diluted with H2O and extracted with EtOAc. The extract was
washed with 1 M aq HCl and was dried over MgSO4, ﬁltered, and
concentrated under vacuum. Pure 18 was obtained as a pale white
powder (0.96 g, 32.5%). m/z (ES), found 198.1024 (C10H13ClNO
[M+H]+) requires 198.0607; dH/ppm (400 MHz, d6-DMSO): 9.59
(1H, s, NH), 7.24 (1H, d, J = 8.0, Ar-H), 7.03 (1H, s, Ar-H), 6.98 (1H,
d, J = 8.1, Ar-H), 4.28 (2H, s, CH2), 2.25 (3H, s, CH3), 2.15 (3H, s, CH3).
4.5.14. 2-Chloro-N-(4-isopropyl-phenyl)-acetamide (19)
Procedure as for 14 except using 4-isopropylaniline (2.1 mL,
15 mmol) and the reaction mixture was allowed to stir at RT over-
night. Pure 19 was obtained as a pale yellow powder (2.0 g, 63%).
m/z (ES), found 212.0961 (C11H15ClNO [M+H]+) requires
212.0764; dH/ppm (400 MHz, d6-DMSO): 10.19 (1H, s, NH), 7.49
(2H, d, J = 8.5, Ar-H), 7.19 (2H, d, J = 8.5, Ar-H), 4.22 (2H, s, CH2),
2.84 (1H, hept, CH of isopropyl), 1.18 [6H, d, J = 6.9, (CH3)2 of
isopropyl].
4.5.15. 2-Chloro-N-(4-triﬂuoromethyl-phenyl)-acetamide (20)
Procedure as for 14 except using 4-triﬂuoromethylaniline
(1.9 mL, 15 mmol). Pure 20 was obtained as a yellow powder
(1.5 g, 42%). m/z (ES), found 235.6225 (C9H6ClF3NO [MH])
requires 236.0168; dH/ppm (400 MHz, d6-DMSO): 10.64 (1H, s,
NH), 7.80 (2H, d, J = 8.5, Ar-H), 7.70 (2H, d, J = 8.6, Ar-H), 4.30
(2H, s, CH2).
4.5.16. N-(3,5-Bis-triﬂuoromethyl-phenyl)-2-chloro-acetamide
(21)
Procedure as for 14 except using 3,5-bis(triﬂuoromethyl)aniline
(2.4 mL, 15 mmol) and the mixture was allowed to stir at RT
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uum dried. Pure 21 was obtained as a brick-red powder (1.77 g,
39%). dH/ppm (400 MHz, d6-DMSO): 10.93 (1H, s, NH), 8.25 (2H,
s, Ar-H), 7.80 (1H, s, Ar-H), 4.34 (2H, s, CH2).
4.5.17. 2-Chloro-N-(4-methoxy-phenyl)-acetamide (22)
Procedure as for 14 except using p-anisidine (1.85 g, 15 mmol).
Pure 22 was obtained as a gray powder (1.77 g, 59%). m/z (ES),
found 200.0450 (C9H11ClNO2 [M+H]+) requires 200.0400; dH/ppm
(400 MHz, d6-DMSO): 10.13 (1H, s, NH), 7.50 (2H, d, J = 9.1,
Ar-H), 6.90 (2H, d, J = 9.1, Ar-H), 4.21 (2H, s, CH2), 3.72 (3H, s,
OCH3).
4.5.18. 2-Chloro-N-(4-chloro-phenyl)-acetamide (23)
Procedure as for 14 except using 4-chloroaniline (1.95 g,
15 mmol). Pure 23 was obtained as a pale yellow powder (2.26 g,
74%). m/z (ES), found 201.6550 (C8H6Cl2NO [MH]) requires
201.9905; dH/ppm (400 MHz, d6-DMSO): 10.41 (1H, s, NH), 7.62
(2H, d, J = 9.0, Ar-H), 7.38 (2H, d, J = 8.9, Ar-H), 4.25 (2H, s, CH2).
4.5.19. N-(4-Bromo-phenyl)-2-chloro-acetamide (24)
To a solution of 4-bromoaniline (2.66 g, 15 mmol) in CH2Cl2
(60 mL) was added Et3N (2.1 mL, 15.2 mmol) and the mixture
was allowed to stir at RT for 10 min. To this was added chloroacetyl
chloride (1.19 mL, 15 mmol) and the reaction was left to stir at RT
for 4 h. The white precipitate formed was separated by ﬁltration
and washed with CH2Cl2. Pure 24 was obtained as a white powder
(898 mg, 24%). m/z (ES), found 247.9191 (C8H8BrClNO [M+H]+)
requires 247.9400; dH/ppm (400 MHz, d6-DMSO): 10.41 (1H, s,
NH), 7.56 (2H, d, J = 9.0, Ar-H), 7.51 (2H, d, J = 9.0, Ar-H), 4.25
(2H, s, CH2).
4.5.20. 2-Chloro-N-thiazol-2-yl-acetamide (25)
Procedure as for 14 except using 2-aminothiazole (1.55 g,
15 mmol). Precipitation was observed within 15 min of the addi-
tion of chloroacetyl chloride. The precipitate was extracted with
EtOAc. Pure 25 was obtained as a pale yellow powder (642 mg,
24%) after recrystallization from EtOH. m/z (ES), found 176.9838
(C5H6ClN2OS [M+H]+) requires 176.9811; dH/ppm (400 MHz, d6-
DMSO): 12.48 (1H, s, NH), 7.50 (1H, d, J = 3.6, Ar-H), 7.27 (1H, d,
J = 3.6, Ar-H), 4.38 (2H, s, CH2).
4.5.21. 2-Chloro-N-(4-methyl-thiazol-2-yl)-acetamide (25a)
Procedure as for 14 except using 2-amino-4-methylthiazole
(1.75 g, 15 mmol). Pure 25a was obtained as a pale yellow powder
(1.4 g, 49%). m/z (ES), found 190.0078 (C6H8ClN2OS [M+H]+)
requires 190.9968; dH/ppm (400 MHz, d6-DMSO): 12.42 (1H, s,
NH), 6.80 (1H, d, J = 1.0, Ar-H), 4.35 (2H, s, CH2), 2.26 (3H, d,
J = 1.0, Ar-H).
4.5.22. 2-Chloro-N-(5-methyl-isoxazol-3-yl)-acetamide (25b)
Procedure as for 14 except using 3-amino-5-methyl-isoxazole
(1.5 g, 15 mmol, 1.00 equiv) and the reaction mixture was allowed
to stir at RT overnight. The precipitate obtained was washed with
CH2Cl2 and then vacuum dried. Pure 25b was obtained as a white
crystalline solid (766 mg, 30%). m/z (ES), found 175.0221 (C6H8-
ClN2O2 [M+H]+) requires 175.0196; dH/ppm (400 MHz, d6-DMSO):
11.25 (1H, s, NH), 6.62 (1H, s, Ar-H), 4.29 (2H, s, CH2), 2.38 (3H,
s, CH3).
4.5.23. 3-Chloro-N-(3,4-dimethyl-phenyl)-propionamide (26)
Procedure as for 14 except using 3-chloropropionyl chloride
(1.44 mL, 15 mmol) and the reaction mixture was allowed to stir
at RT overnight. The precipitate obtained was washed with PE
and then vacuum dried. Pure 26 was obtained as a white powder
(1.9 g, 60%). m/z (ES), found 212.1006 (C11H15ClNO [M+H]+)requires 212.0764; dH/ppm (400 MHz, d6-DMSO): 9.87 (1H, s,
NH), 7.37 (1H, s, Ar-H), 7.31 (1H, dd, J = 2.1 + 8.1, Ar-H), 7.04 (1H,
d, J = 8.1, Ar-H), 3.86 (2H, t, J = 6.3, CH2), 2.78 (2H, t, J = 6.3, CH2),
2.19 (3H, s, CH3), 2.16 (3H, s, CH3).
4.5.31. N-(2,5-Dimethyl-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (1a)
A solution of 6 (333 mg, 1 mmol) in DMF (3 mL), and a solution
of 17 (198 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
mixture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (75 mL) and
allowed to stand for a few hours. The mixture was then extracted
with EtOAc. The combined extracts were washed with distilled
H2O, dried over Na2SO4, ﬁltered, and concentrated under vacuum.
Puriﬁcation of the crude product by ﬂash column chromatography
(FCC; EtOAc, Rf = 0.26) gave pure 1a as a pale white powder
(196 mg, 40%). dH/ppm (400 MHz, d6-DMSO): 9.57 (1H, s, NH),
7.63 (1H, dd, J = 0.7 + 1.7, Ar-H), 7.22 (1H, s, Ar-H), 7.05 (1H, d,
J = 7.7, Ar-H), 6.97 (1H, s, Ar-H), 6.88 (1H, d, J = 7.7, Ar-H), 6.48–
6.42 (2H, m, Ar-H), 5.39 (2H, s, CH2), 4.65 (2H, s, CH2), 4.11 (2H,
s, CH2), 2.33 [6H, s, (CH3)2], 2.23 (3H, s, CH3), 2.06 (3H, s, CH3).
4.5.32. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide
(27)
Procedure as for 1a except using 2-bromoacetamide (138 mg,
1 mmol) and the reaction was carried out for 48 h. The white pre-
cipitate formed was collected by ﬁltration, washed with H2O and
lyophilized, followed by recrystallization from EtOH. Pure 27 was
obtained as a pale white powder (173 mg, 45%). m/z (ES), found
389.0885 (C16H17N6O2S2 [MH]) requires 389.0933; dH/ppm
(400 MHz, d6-DMSO): 7.57–7.70 (2H, m, Ar-H), 7.20 (1H, br s,
OH), 6.99 (1H, s, =NH), 6.40–6.50 (2H, m, Ar-H), 5.36 (2H, s, CH2),
4.64 (2H, s, CH2), 3.85 (2H, s, CH2), 2.34 (6H, s, 2CH3).
4.5.33. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-thiazol-2-yl-
acetamide (28)
Procedure as for 1a except using 25 (177 mg, 1 mmol) and the
reaction was carried out for 24 h. The precipitate formed was col-
lected by ﬁltration, washed thoroughly with water and lyophilized,
followed by recrystallization fromMeOH. Pure 28 (EtOAc, Rf = 0.06)
was obtained as a white powder (292 mg, 62%). m/z (ES), found
474.6843 (C19H20N7O2S3 [M+H]+) requires 474.0762; dH/ppm
(400 MHz, d6-DMSO): 12.38 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8,
Ar-H), 7.47 (1H, d, J = 3.6, Ar-H), 7.22 (1H, d, J = 3.6, Ar-H), 6.98
(1H, s, Ar-H), 6.52–6.40 (2H, m, Ar-H), 5.38 (2H, s, CH2), 4.63 (2H,
s, CH2), 4.19 (2H, s, CH2), 2.34 (6H, s, 2CH3).
4.5.34. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-methyl-
thiazol-2-yl)-acetamide (29)
Procedure as for 1a except using 25a (191 mg, 1 mmol) and the
reaction was carried out for 48 h. The mixture was extracted with
EtOAc. The combined extracts were washed with H2O and dried
over Na2SO4, ﬁltered, and concentrated under vacuum. Puriﬁcation
of the crude product by FCC (EtOAc–MeOH (95:5) gave 29 as a pale
white powder (219 mg, 45%). m/z (ES), found 486.0944 (C20H20N7-
O2S3 [MH]) requires 486.0919; dH/ppm (400 MHz, d6-DMSO):
12.29 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H), 6.98 (1H, s,
Ar-H), 6.76 (1H, d, J = 1.0, Ar-H), 6.50–6.40 (2H, m, Ar-H), 5.37
(2H, s, CH2), 4.63 (2H, s, CH2), 4.16 (2H, s, CH2), 2.34 (6H, s,
2CH3), 2.25 (3H, d, J = 0.9, CH3).
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furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(5-methyl-
isoxazol-3-yl)-acetamide (30)
Procedure as for 1a except using 25b (175 mg, 1 mmol) and the
reaction was carried out for 48 h. The precipitate was collected by
ﬁltration, washed with H2O and lyophilized, followed by recrystal-
lization from MeOH. Pure 30 was obtained as a white powder
(298 mg, 65%). m/z (ES), found 472.1485 (C20H22N7O3S2 [M+H]+)
requires 472.1147; dH/ppm (400 MHz, d6-DMSO): 11.20 (1H, s,
NH), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H), 6.99 (1H, s, Ar-H), 6.56 (1H,
s, Ar-H), 6.48–6.42 (2H, m, Ar-H), 5.37 (2H, s, CH2), 4.63 (2H, s,
CH2), 4.11 (2H, s, CH2), 2.36 (3H, d, J = 0.8, CH3), 2.34 (6H, s, 2CH3).
4.5.36. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-phenyl-
acetamide (31)
Procedure as for 1a except using 6 (600 mg, 1.8 mmol) and 14
(305 mg, 1.8 mmol). The mixture was extracted with EtOAc. The
combined extracts were washed with H2O and dried over Na2SO4,
ﬁltered, and concentrated under vacuum. Puriﬁcation of the crude
product by FCC (EtOAc, Rf = 0.20), gave 31 as a pale white powder
(586 mg, 70%). m/z (ES), found 465.1360 (C22H21N6O2S2 [MH])
requires 465.1246; dH/ppm (400 MHz, d6-DMSO): 10.28 (1H, s,
NH), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H), 7.50–7.56 (2H, m, Ar-H),
7.26–7.32 (2H, m, Ar-H), 7.05 (1H, t, J = 7.4, Ar-H), 6.98 (1H, s,
Ar-H), 6.42–6.49 (2H, m, Ar-H), 5.39 (2H, s, CH2), 4.64 (2H, s,
CH2), 4.11 (2H, s, CH2), 2.34 (6H, s, 2CH3).
4.5.37. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-m-tolyl-
acetamide (32)
Procedure as for 1a except using 15 (184 mg, 1 mmol) and the
reaction was carried out for 24 h. The mixture was extracted with
EtOAc. The combined extracts were washed with H2O and dried
over Na2SO4, ﬁltered, and concentrated under vacuum. Puriﬁcation
of the crude product by FCC (EtOAc, Rf = 0.21), gave 32 as a pale
white powder (264 mg, 55%). m/z (ES), found 479.1382 (C23H23N6-
O2S2 [MH]) requires 479.1402; dH/ppm (400 MHz, d6-DMSO):
10.20 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H), 7.37 (1H, s,
Ar-H), 7.31 (1H, d, J = 8.3, Ar-H), 7.17 (1H, t, J = 7.7/7.9, Ar-H),
6.98 (1H, s, Ar-H), 6.87 (1H, d, J = 7.5, Ar-H), 6.42–6.49 (2H, m,
Ar-H), 5.39 (2H, s, CH2), 4.64 (2H, s, CH2), 4.09 (2H, s, CH2), 2.34
(6H, s, 2CH3), 2.27 (3H, s, CH3).
4.5.38. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-p-tolyl-
acetamide (33)
Procedure as for 1a except using 16 (184 mg, 1 mmol). The mix-
ture was extracted with EtOAc. The combined extracts were
washed with H2O and dried over Na2SO4, ﬁltered, and concentrated
under vacuum followed by recrystallization from MeOH. Pure 33
was obtained as a white crystalline solid (195 mg, 40%). m/z (ES),
found 479.1350 (C23H23N6O2S2 [MH]) requires 479.1402; dH/
ppm (400 MHz, d6-DMSO): 10.19 (1H, s, NH), 7.63 (1H, dd,
J = 0.8 + 1.8, Ar-H), 7.41 (2H, d, J = 8.5, Ar-H), 7.09 (2H, d, J = 8.3,
Ar-H), 6.98 (1H, s, Ar-H), 6.41–6.49 (2H, m, Ar-H), 5.39 (2H, s,
CH2), 4.64 (2H, s, CH2), 4.08 (2H, s, CH2), 2.34 (6H, s, 2CH3), 2.24
(3H, s, CH3).
4.5.39. N-(2,4-Dimethyl-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (34)
Procedure as for 1a except using 6 (200 mg, 0.6 mmol), 18
(118 mg, 0.6 mmol) and the reaction was carried out for 48 h.
The mixture was extracted with EtOAc. The combined extracts
were washed with H2O and dried over Na2SO4, ﬁltered, and con-centrated under vacuum. Puriﬁcation of the crude product by
FCC (EtOAc, Rf = 0.23), gave 34 as a pale white powder (147 mg,
50%). m/z (ES), found 493.1446 (C24H25N6O2S2 [MH]) requires
493.1559; dH/ppm (400 MHz, d6-DMSO): 9.55 (1H, s, NH), 7.65–
7.62 (1H, m, Ar-H), 7.23 (1H, d, J = 8.0, Ar-H), 7.01–6.90 (3H, m,
Ar-H), 6.48–6.42 (2H, m, Ar-H), 5.39 (2H, s, CH2), 4.65 (2H, s,
CH2), 4.09 (2H, s, CH2), 2.33 (6H, s, 2CH3), 2.23 (3H, s, CH3), 2.06
(3H, s, CH3).
4.5.40. N-(3,4-Dimethyl-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (35)
A solution of 6 (1.0 g, 3 mmol) in DMF (8 mL) and a solution of
13 (593 mg, 3 mmol) in DMF (4 mL) were combined in a dry Rad-
leys reaction tube containing K2CO3 (442 mg, 3.2 mmol). The mix-
ture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (50 mL) and
allowed to stand for few hours. The brown precipitate formed
was collected by ﬁltration, washed with H2O and lyophilized, fol-
lowed by recrystallization from EtOH–MeOH (1:1). Pure 35 was
obtained as a pale yellow crystalline solid (952 mg, 64%). m/z
(ES), found 495.1811 (C24H27N6O2S2 [M+H]+) requires 495.1559;
dH/ppm (400 MHz, d6-DMSO): 10.14 (1H, s, NH), 7.64 (1H, dd,
J = 0.8 + 1.8, Ar-H), 7.31 (1H, d, J = 1.8, Ar-H), 7.24 (1H, dd,
J = 2.1 + 8.1, Ar-H), 7.03 (1H, d, J = 8.2, Ar-H), 6.98 (1H, s, Ar-H),
6.50–6.41 (2H, m, Ar-H), 5.39 (2H, s, CH2), 4.64 (2H, s, CH2), 4.07
(2H, s, CH2), 2.33 (6H, s, 2CH3), 2.17 (3H, s, CH3), 2.15 (3H, s, CH3).
4.5.41. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
isopropyl-phenyl)-acetamide (36)
Procedure as for 1a except using 19 (211 mg, 1 mmol). The mix-
ture was extracted with EtOAc. The combined extracts were
washed with H2O and dried over Na2SO4, ﬁltered, and concentrated
under vacuum. Puriﬁcation of the crude product by FCC (EtOAc,
Rf = 0.21), gave 36 as a pale white powder (300 mg, 59%). m/z
(ES), found 509.7175 (C25H29N6O2S2 [M+H]+) requires 509.1715;
dH/ppm (400 MHz, d6-DMSO): 10.20 (1H, s, NH), 7.63 (1H, dd,
J = 0.8 + 1.8, Ar-H), 7.43 (2H, d, J = 8.6, Ar-H), 7.16 (2H, d, J = 8.5,
Ar-H), 6.98 (1H, s, Ar-H), 6.48–6.42 (2H, m, Ar-H), 5.39 (2H, s,
CH2), 4.64 (2H, s, CH2), 4.08 (2H, s, CH2), 2.83 (1H, hept, CH of iso-
propyl), 2.34 (6H, s, 2CH3), 1.17 [6H, d, J = 6.9, (CH3)2].
4.5.42. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-
furan-2-ylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
triﬂuoromethyl-phenyl)-acetamide (37)
Procedure as for 1a except using 20 (238 mg, 1 mmol). The pre-
cipitate was collected by ﬁltration, washed with H2O and lyophi-
lized, followed by recrystallization from MeOH. Pure 37 was
obtained as a white powder (314 mg, 59%). m/z (ES), found
535.6185 (C23H22F3N6O2S2 [M+H]+) requires 535.1119; dH/ppm
(400 MHz, d6-DMSO): 10.65 (1H, s, NH), 7.74 (2H, d, J = 8.6, Ar-
H), 7.67 (2H, d, J = 8.7, Ar-H), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H),
6.98 (1H, s, Ar-H), 6.48–6.42 (2H, m, Ar-H), 5.39 (2H, s, CH2),
4.64 (2H, s, CH2), 4.15 (2H, s, CH2), 2.33 (6H, s, 2CH3).
4.5.43. N-(3,5-Bis-triﬂuoromethyl-phenyl)-2-[5-(4,6-dimethyl-
pyrimidin-2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-
[1,2,4]triazol-3-ylsulfanyl]-acetamide (38)
Procedure as for 1a except using 21 (306 mg, 1 mmol) and the
reaction was carried out for 48 h. The precipitate was collected
by ﬁltration, washed with H2O and lyophilized, followed by recrys-
tallization from EtOH. Pure 38 was obtained as a white powder
(264 mg, 44%). m/z (ES), found 603.9979 (C24H21F6N6O2S2
[M+H]+) requires 603.0993; dH/ppm (400 MHz, d6-DMSO): 10.95
(1H, s, NH), 8.20 (2H, s, Ar-H), 7.78 (1H, s, Ar-H), 7.63 (1H, dd,
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(2H, s, CH2), 4.63 (2H, s, CH2), 4.16 (2H, s, CH2), 2.33 (6H, s, 2CH3).
4.5.44. N-(4-Chloro-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (39)
Procedure as for 1a except using 23 (204 mg, 1 mmol) and the
reaction was carried out for 24 h. The precipitate was collected
by ﬁltration, washed with H2O and lyophilized, followed by recrys-
tallization from EtOH–MeOH (1:1). Pure 39 was obtained as a
white powder (227 mg, 46%). m/z (ES), found 500.6534 (C22H22-
ClN6O2S2 [M+H]+) requires 501.0856; dH/ppm (400 MHz, d6-
DMSO): 10.42 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8, Ar-H), 7.56
(2H, d, J = 8.9, Ar-H), 7.35 (2H, d, J = 8.9, Ar-H), 6.98 (1H, s, Ar-H),
6.49–6.42 (2H, m, Ar-H), 5.39 (2H, s, CH2), 4.64 (2H, s, CH2), 4.10
(2H, s, CH2), 2.33 (6H, s, 2CH3).
4.5.45. N-(4-Bromo-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (40)
Procedure as for 1a except using 6 (200 mg, 0.6 mmol), 24
(149 mg, 0.6 mmol) and the reaction was carried out for 36 h.
The precipitate was collected by ﬁltration, washed with H2O and
lyophilized, followed by recrystallization from MeOH. Pure 40
was obtained as a white powder (185 mg, 57%). m/z (ES), found
544.9952 (C22H22BrN6O2S2 [M+H]+) requires 545.0351; dH/ppm
(400 MHz, d6-DMSO): 10.41 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8,
Ar-H), 7.54–7.45 (4H, m, Ar-H), 6.98 (1H, s, Ar-H), 6.48–6.42 (2H,
m, Ar-H), 5.39 (2H, s, CH2), 4.63 (2H, s, CH2), 4.10 (2H, s, CH2),
2.34 (6H, s, 2CH3).
4.5.46. 2-[4-Allyl-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(3,4-
dimethyl-phenyl)-acetamide (41)
A solution of 7 (293 mg, 1 mmol) in DMF (3 mL) and a solution
of 13 (198 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
mixture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (50 mL) and
allowed to stand for few hours. The brown precipitate formed
was collected by ﬁltration, washed with H2O and lyophilized, fol-
lowed by recrystallization from EtOH. Pure 41was obtained as pale
white crystals (96 mg, 21%). m/z (ES), found 453.1533 (C22H25N6-
OS2 [MH]) requires 453.1610; dH/ppm (400 MHz, d6-DMSO):
10.10 (1H, s, NH), 7.30 (1H, d, J = 1.8, Ar-H), 7.24 (1H, dd,
J = 2.1 + 8.1, Ar-H), 7.04 (1H, d, J = 8.2, Ar-H), 7.00 (1H, s, Ar-H),
6.04–5.83 (1H, m, CH of allyl), 5.20 [1H, dd, J = 1.0 + 10.4, N-CH2
(Ha)], 4.91 [1H, dd, J = 1.0 + 17.2, N-CH2 (Hb)], 4.73 (2H, d, J = 5.0,
@CH2), 4.55 (2H, s, CH2), 4.05 (2H, s, CH2), 2.35 (6H, s, 2CH3),
2.17 (3H, s, CH3), 2.15 (3H, s, CH3).
4.5.47. N-(3,4-Dimethyl-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-(3-methoxy-propyl)-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (42)
A solution of 8 (325 mg, 1 mmol) in DMF (3 mL) and a solution
of 13 (198 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
mixture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (50 mL) and
allowed to stand for few hours. The precipitate formed was col-
lected by ﬁltration, washed with H2O and lyophilized, followed
by recrystallization from EtOH. Pure 42 was obtained as a crystal-
line white solid (317 mg, 65%). m/z (ES), found 487.1689 (C23H31-
N6O2S2 [M+H]+) requires 487.1872; dH/ppm (400 MHz, d6-DMSO):
10.11 (1H, s, NH), 7.30 (1H, s, Ar-H), 7.24 (1H, d, J = 8.1, Ar-H),
7.04 (1H, d, J = 8.0, Ar-H), 7.00 (1H, s, Ar-H), 4.58 (2H, s, CH2),4.10 (2H, t, J = 7.2, CH2OCH3), 4.08 (2H, s, CH2), 3.29 (2H, t, J = 5.8,
N-CH2), 3.21 (3H, d, J = 1.7, OCH3), 2.35 (6H, s, 2CH3), 2.17 (3H, s,
CH3), 2.15 (3H, s, CH3), 1.98–1.86 (2H, m, CH2).
4.5.48. N-(3,4-Dimethyl-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-(4-methoxy-phenyl)-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (43)
A solution of 9 (360 mg, 1 mmol, 1 equiv) in DMF (4 mL) and a
solution of 13 (198 mg, 1 mmol) in DMF (2 mL) were combined in a
dry Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol).
The mixture was allowed to stir at 40 C for 36 h in a Radleys par-
allel synthesizer. The mixture was poured on crushed ice (25 mL)
and allowed to stand for few hours. The precipitate formed was
collected by ﬁltration, washed with H2O and lyophilized. Pure 43
was obtained as a pale yellow powder (469 mg, 90%). m/z (ES),
found 519.1627 (C26H27N6O2S2 [MH]) requires 519.1715; dH/
ppm (400 MHz, d6-DMSO): 10.13 (1H, s, NH), 7.35 (2H, d, J = 8.9,
Ar-H), 7.32–7.23 (2H, m, Ar-H), 7.04 (1H, d, J = 8.2, Ar-H), 6.99
(2H, d, J = 8.9, Ar-H), 6.91 (1H, s, Ar-H), 4.46 (2H, s, CH2), 4.08
(2H, s, CH2), 3.78 (3H, s, OCH3), 2.27 (6H, s, 2CH3), 2.17 (3H, s,
CH3), 2.16 (3H, s, CH3).
4.5.49. 2-[4-(4-Chloro-phenyl)-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(3,4-
dimethyl-phenyl)-acetamide (44)
A solution of 10 (364 mg, 1 mmol) in DMF (3 mL) and a solution
of 13 (198 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
mixture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (50 mL) and
allowed to stand for few hours. The brown precipitate formed
was collected by ﬁltration, washed with H2O and lyophilized.
Without any further puriﬁcation, 44 was obtained as a white pow-
der (481 mg, 92%). m/z (ES), found 523.1134 (C25H24ClN6OS2
[MH]) requires 523.1220; dH/ppm (400 MHz, d6-DMSO): 10.11
(1H, s, NH), 7.55–7.46 (4H, m Ar-H), 7.33–7.22 (2H, m, Ar-H),
7.04 (1H, d, J = 8.14, Ar-H), 6.92 (1H, s, Ar-H), 4.51 (2H, s, CH2),
4.08 (2H, s, CH2), 2.27 (6H, s, 2CH3), 2.18 (3H, s, CH3), 2.16 (3H, s,
CH3).
4.5.50. N-(3,4-Dimethyl-phenyl)-3-[5-(4,6-dimethyl-pyrimidin-
2-ylsulfanylmethyl)-4-furan-2-ylmethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-propionamide (45)
Procedure as for 1a except using 26 (212 mg, 1 mmol) and the
reaction was carried out for 36 h. The mixture was extracted with
EtOAc. The combined extracts were washed with H2O and dried
over Na2SO4, ﬁltered, and concentrated under vacuum. Puriﬁcation
of the crude product by FCC (EtOAc, Rf = 0.12), gave 45 as a pale
white powder (127 mg, 25%). m/z (ES), found 509.1672 (C25H29N6-
O2S2 [M+H]+) requires 509.1715; dH/ppm (400 MHz, d6-DMSO):
9.83 (1H, s, NH), 7.60 (1H, dd, J = 0.9 + 1.7, Ar-H), 7.35 (1H, d,
J = 1.8, Ar-H), 7.28 (1H, dd, J = 2.1 + 8.1, Ar-H), 7.03 (1H, d, J = 8.2,
Ar-H), 7.00 (1H, s, Ar-H), 6.43–6.37 (2H, m, Ar-H), 5.30 (2H, s,
CH2), 4.64 (2H, s, CH2), 3.34 (2H, t, J = 6.8, CH2), 2.76 (2H, t,
J = 6.7/6.8, CH2), 2.34 (6H, s, 2CH3), 2.17 (3H, s, CH3), 2.15 (3H, s,
CH3).
4.5.51. 2-[4-Allyl-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
isopropyl-phenyl)-acetamide (46)
Procedure as for 1a except using 19 (212 mg, 1 mmol) and the
reaction was carried out for 22 h. The mixture was extracted with
EtOAc. The combined extracts were washed H2O and dried over
Na2SO4, ﬁltered, and concentrated under vacuum. Puriﬁcation of
the crude product by FCC (EtOAc, Rf = 0.16), gave 46 as a pale white
powder (228 mg, 49%). m/z (ES), found 469.2179 (C23H29N6OS2
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(1H, s, NH), 7.43 (2H, d, J = 8.5, Ar-H), 7.16 (2H, d, J = 8.5, Ar-H),
7.00 (1H, s, Ar-H), 5.99–5.84 (1H, m, CH of allyl), 5.20 [1H, dd,
J = 1.0 + 10.4, N-CH2 (Ha)], 4.91 [1H, dd, J = 0.9 + 17.2, N-CH2
(Hb)], 4.74 (2H, d, J = 4.9, @CH2), 4.55 (2H, s, CH2), 4.07 (2H, s,
CH2), 2.83 (1H, hept, CH of isopropyl), 2.35 (6H, s, 2CH3), 1.17
(6H, d, J = 6.9, (CH3)2 of isopropyl).
4.5.52. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(3-
methoxy-propyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
isopropyl-phenyl)-acetamide (47)
Procedure as for 1a except using 19 (212 mg, 1 mmol) and the
reaction was carried out for 42 h. The precipitate formed was col-
lected, washed with H2O and lyophilized, followed by recrystalliza-
tion from EtOH. Pure 47 was obtained as a white powder (382 mg,
76%). m/z (ES), found 501.7603 (C24H33N6O2S2 [M+H]+) requires
501.2028; dH/ppm (400 MHz, d6-DMSO): 10.21 (1H, s, NH), 7.43
(2H, d, J = 8.6, Ar-H), 7.16 (2H, d, J = 8.5, Ar-H), 7.00 (1H, s, Ar-H),
4.58 (2H, s, CH2), 4.10 (2H, s, CH2), 4.10 (2H, t, J = 7.2, CH2OCH3, this
peak is partly covered by CH2 peak at 4.10), 3.28 (2H, t, J = 5.8, N-
CH2), 3.20 (3H, s, OCH3), 2.83 (1H, hept, CH of isopropyl), 2.36 (6H,
s, 2CH3), 1.98–1.87 (2H, m, CH2), 1.17 [6H, d, J = 6.9, (CH3)2 of
isopropyl].
4.5.53. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(4-
methoxy-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
isopropyl-phenyl)-acetamide (48)
A solution of 9 (360 mg, 1 mmol) in DMF (4 mL) and a solution
of 19 (212 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
mixture was allowed to stir at 40 C overnight in a Radleys parallel
synthesizer. The mixture was poured on crushed ice (50 mL) and
allowed to stand for few hours. The precipitate formed was col-
lected by ﬁltration, washed with H2O and lyophilized. The dried
precipitate was washed with hot EtOH–MeOH (1:1) to afford 48
as a white powder (466 mg, 87%). m/z (ES), found 535.1592 (C27-
H31N6O2S2 [M+H]+) requires 535.1872; dH/ppm (400 MHz, d6-
DMSO): 10.22 (1H, s, NH), 7.45 (2H, d, J = 8.6, Ar-H), 7.35 (2H, d,
J = 8.8, Ar-H), 7.17 (2H, d, J = 8.5, Ar-H), 6.98 (2H, d, J = 8.9, Ar-H),
6.91 (1H, s, Ar-H), 4.46 (2H, s, CH2), 4.09 (2H, s, CH2), 3.77 (3H, s,
OCH3), 2.83 (1H, hept, CH of isopropyl), 2.26 (6H, s, 2CH3), 1.17
[6H, d, J = 6.9, (CH3)2 of isopropyl].
4.5.54. 2-[4-(4-Chloro-phenyl)-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
isopropyl-phenyl)-acetamide (49)
Procedure as for 1a except using 19 (212 mg, 1 mmol). The pre-
cipitate formed was collected, washed with H2O, then lyophilized.
The dried precipitate was washed with hot EtOH to afford 49 as a
white powder (330 mg, 62%). m/z (ES), found 539.1047 (C26H28-
ClN6OS2 [M+H]+) requires 539.1376; dH/ppm (400 MHz, d6-DMSO):
10.20 (1H, s, NH), 7.55–7.47 (4H, m, Ar-H), 7.43 (2H, d, J = 8.5, Ar-
H), 7.17 (2H, d, J = 8.5, Ar-H), 6.92 (1H, s, Ar-H), 4.51 (2H, s, CH2),
4.08 (2H, s, CH2), 2.83 (1H, hept, CH of isopropyl), 2.27 (6H, s,
2CH3), 1.17 [6H, d, J = 6.9, (CH3)2 of isopropyl].
4.5.55. 2-[4-Allyl-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
triﬂuoromethyl-phenyl)-acetamide (50)
Procedure as for 1a except using 20 (238 mg, 1 mmol). The
brown precipitate formed was collected, washed with H2O and
lyophilized, followed by recrystallization from EtOH. Pure 50 was
obtained as a white powder (104 mg, 21%). m/z (ES), found
493.1109 (C21H20 F3N6OS2 [MH]) requires 493.1170; dH/ppm
(400 MHz, d6-DMSO): 10.64 (1H, s, NH), 7.74 (2H, d, J = 8.6, Ar-
H), 7.70 (2H, d, J = 8.8, Ar-H), 6.99 (1H, s, Ar-H), 6.00–5.84 (1H,m, CH of allyl), 5.20 [1H, d, J = 10.4, N-CH2 (Ha)], 4.92 (1H, d,
J = 17.2, N-CH2 (Hb)], 4.74 (2H, d, J = 4.9, @CH2), 4.55 (2H, s, CH2),
4.13 (2H, s, CH2), 2.35 (6H, s, 2CH3).
4.5.56. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(3-
methoxy-propyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
triﬂuoromethyl-phenyl)-acetamide (51)
Procedure as for 1a except using 20 (238 mg, 1 mmol). The pre-
cipitate formed was collected, washed with H2O and lyophilisation,
followed by recrystallization from EtOH. Pure 51was obtained as a
white powder (384 mg, 73%). m/z (ES), found 525.1343 (C22H24F3-
N6O2S2 [MH]) requires 525.1433; dH/ppm (400 MHz, d6-DMSO):
10.65 (1H, s, NH), 7.74 (2H, d, J = 8.5, Ar-H) 7.67 (2H, d, J = 8.2, Ar-
H), 7.00 (1H, s, Ar-H), 4.58 (2H, s, CH2), 4.16 (2H, s, CH2), 4.10 (2H, t,
J = 6.7/7.6, CH2OCH3), 3.29 (2H, t, J = 5.8, N-CH2), 3.20 (3H, d, J = 2.2,
OCH3), 2.35 (6H, s, 2CH3), 1.98–1.87 (2H, m, CH2).
4.5.57. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(4-
methoxy-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
triﬂuoromethyl-phenyl)-acetamide (52)
Procedure as for 1a except using 20 (238 mg, 1 mmol) and the
reaction was carried out for 24 h. The precipitate formed was col-
lected, washed with H2O, then lyophilized. The dried precipitate
was washed with EtOH–MeOH (1:1) to afford 52 as a yellow pow-
der (391 mg, 70%). m/z (ES), found 561.0706 (C25H24F3N6O2S2
[M+H]+) requires 561.1276; dH/ppm (400 MHz, d6-DMSO): 10.67
(1H, s, NH), 7.76 (2H, d, J = 7.9, Ar-H), 7.68 (2H, d, J = 7.7, Ar-H),
7.36 (2H, d, J = 8.8, Ar-H), 6.99 (2H, d, J = 8.8, Ar-H), 6.91 (1H, s,
Ar-H), 4.46 (2H, s, CH2), 4.15 (2H, s, CH2), 3.78 (3H, d, J = 1.6,
OCH3), 2.27 (6H, s, 2CH3).
4.5.58. 2-[4-(4-Chloro-phenyl)-5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
triﬂuoromethyl-phenyl)-acetamide (53)
Procedure as for 1a except using 20 (238 mg, 1 mmol) and the
reaction was carried out for 24 h. The precipitate formed was col-
lected, washed with H2O and lyophilized. The dried precipitate was
washed with EtOH–MeOH (1:1) to afford 53 as an off-white pow-
der (460 mg, 81%). m/z (ES), found 565.0165 (C24H20ClF3N6OS2
[M+H]+) requires 565.0781; dH/ppm (400 MHz, d6-DMSO): 10.65
(1H, s, NH), 7.75 (2H, d, J = 8.4, Ar-H), 7.68 (2H, d, J = 8.1, Ar-H),
7.56–7.45 (4H, m, Ar-H), 6.92 (1H, s, Ar-H), 4.51 (2H, s, CH2),
4.15 (2H, s, CH2), 2.26 (6H, s, 2CH3).
4.5.59. N-(3,5-Bis-triﬂuoromethyl-phenyl)-2-[5-(4,6-dimethyl-
pyrimidin-2-ylsulfanylmethyl)-4-(4-methoxy-phenyl)-4H-
[1,2,4]triazol-3-ylsulfanyl]-acetamide (54)
Procedure as for 1a except using 21 (306 mg, 1 mmol) and the
reaction was carried out for 36 h. The precipitate formed was col-
lected, washed with H2O and lyophilized. Without any further
puriﬁcation, 54 was obtained as a pale yellow powder (526 mg,
83%). m/z (ES), found 627.1069 (C26H21F6N6O2S2 [MH]) requires
627.1150; dH/ppm (400 MHz, d6-DMSO): 10.97 (1H, s, NH), 8.21
(2H, s, Ar-H), 7.78 (1H, s, Ar-H), 7.36 (2H, d, J = 8.9, Ar-H), 6.99
(2H, d, J = 8.9, Ar-H), 6.90 (1H, s, Ar-H), 4.46 (2H, s, CH2), 4.14
(2H, s, CH2), 3.78 (3H, s, OCH3), 2.26 (6H, s, 2CH3).
4.5.60. N-(4-Chloro-phenyl)-2-[5-(4,6-dimethyl-pyrimidin-2-
ylsulfanylmethyl)-4-(4-methoxy-phenyl)-4H-[1,2,4]triazol-3-
ylsulfanyl]-acetamide (55)
Procedure as for 1a except using 23 (204 mg, 1 mmol) and the
reaction was carried out for 42 h. The precipitate formed was col-
lected, washed with H2O, and lyophilized. The dried precipitate
was washed with EtOH–MeOH (1:1) to afford 55 as a white powder
(462 mg, 88%). m/z (ES), found 527.0793 (C24H24ClN6O2S2 [M+H]+)
requires 527.1012; dH/ppm (400 MHz, d6-DMSO): 10.44 (1H, s,
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d, J = 8.9, Ar-H), 6.99 (2H, d, J = 8.9, Ar-H), 6.91 (1H, s, Ar-H), 4.46
(2H, s, CH2), 4.11 (2H, s, CH2), 3.78 (3H, s, OCH3), 2.26 (6H, s, 2CH3).
4.5.61. 2-[5-(4,6-Dimethyl-pyrimidin-2-ylsulfanylmethyl)-4-(4-
methoxy-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(4-
methoxy-phenyl)-acetamide (56)
Procedure as for 1a except using 22 (200 mg, 1 mmol) and the
reaction was carried out for 42 h. The precipitate formed was col-
lected, washed with H2O and lyophilized. The dried precipitate was
washed with MeOH to afford 56 as a white powder (476 mg, 91%).
m/z (ES), found 523.1320 (C25H27N6O3S2 [M+H]+) requires
523.1508; dH/ppm (400 MHz, d6-DMSO): 10.16 (1H, s, NH), 7.45
(2H, d, J = 9.1, Ar-H), 7.35 (2H, d, J = 9.0, Ar-H), 6.99 (2H, d, J = 8.9,
Ar-H), 6.91 (1H, s, Ar-H), 6.88 (2H, d, J = 9.1, Ar-H), 4.46 (2H, s,
CH2), 4.08 (2H, s, CH2), 3.78 (3H, s, OCH3), 3.71 (3H, s, OCH3),
2.27 (6H, s, 2CH3).
4.5.62. 4-Furan-2-ylmethyl-5-methyl-4H-[1,2,4]triazole-3-thiol
(58)
To a solution of 57 (4 g, 48.6 mmol) in EtOH (100 mL) was
added furfuryl isothiocyanate (7.0 mL, 48.6 mmol) and the mixture
was heated under reﬂux overnight. The reaction was cooled and
concentrated under vacuum. The yellow precipitate obtained was
washed with PE–EtOH (1:1). To the pale white precipitate thus
obtained was added 2 M aq NaOH (30 mL) and the mixture was
heated at 45 C for 90 min before cooling. The reaction was neu-
tralized with 10% aq HCl. The resulting white precipitate was
washed with H2O and was lyophilized. Pure 58 was obtained as a
white powder (3.7 g, 39%). m/z (ES), found 196.0995 (C8H10N3OS
[M+H]+) requires 196.0466; dH/ppm (400 MHz, d6-DMSO): 13.53
(1H, s, NH of thione tautomer), 7.62 (1H, t, J = 1.3/1.4, Ar-H), 6.43
(2H, d, J = 1.4, Ar-H), 5.22 (2H, s, CH2), 2.33 (3H, s, CH3).
4.5.63. 4-Allyl-5-methyl-4H-[1,2,4]triazole-3-thiol (59)
To a solution of 57 (4 g, 48.6 mmol) in EtOH (100 mL) was
added allyl isothiocyanate (5 mL, 48.6 mmol) and the mixture
was heated under reﬂux overnight. The reaction was cooled and
concentrated under vacuum. The yellow precipitate obtained was
washed with Et2O. To the white precipitate thus obtained was
added 2 M aq NaOH (40 mL) and the mixture was heated at 45 C
for 60 min before cooling. The reaction was neutralized with 10%
aq HCl. No precipitate was observed and the solution was allowed
to stand overnight. The white crystalline solid thus formed was
collected by ﬁltration, washed with H2O and lyophilised. Pure 59
was obtained as a white crystalline solid (1.42 g, 19%). m/z (ES),
found 156.1384 (C6H10N3S [M+H]+) requires 156.0517; dH/ppm
(400 MHz, d6-DMSO): 13.48 (1H, s, NH of thione tautomer), 5.94–
5.79 (1H, m, CH), 5.19 [1H, dd, J = 1.3 + 10.4, N-CH2 (Ha)], 5.00
[1H, dd, J = 1.3 + 17.2, N-CH2 (Hb)], 4.60 (2H, d, J = 5.2, @CH2),
2.26 (3H, s, CH3).
4.5.64. 4-(3-Methoxy-propyl)-5-methyl-4H-[1,2,4]triazole-3-
thiol (60)
To a solution of 57 (4 g, 48.6 mmol) in EtOH (100 mL) was
added 3-methoxypropyl isothiocyanate (6.2 mL, 48.6 mmol) and
the mixture was heated under reﬂux overnight. The reaction was
cooled and concentrated under vacuum. A colourless oil was
obtained, to which 1 M aq NaOH (20 mL) was added. The mixture
was heated at 45 C for 60 min, before cooling. The reaction was
neutralized with 10% aq HCl. No precipitate was observed. The
mixture was extracted with EtOAc, dried over NaSO4 and concen-
trated under vacuum. Pure 60 was obtained as a white powder
(4.36 g, 48%). m/z (ES), found 188.0792 (C7H14N3OS [M+H]+)
requires 188.0779; dH/ppm (400 MHz, d6-DMSO): 13.40 (1H, s,
NH of thione tautomer), 3.94 (2H, t, J = 7.3, CH2-OCH3), 3.33 (2H,t, J = 6.0, N-CH2), 3.23 (3H, s, OCH3), 2.30 (3H, s, CH3), 1.94–1.85
(2H, m, CH2).
4.5.65. N-(3,4-Dimethyl-phenyl)-2-(4-furan-2-ylmethyl-5-
methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-acetamide (62)
A solution of 58 (195 mg, 1 mmol) in DMF (3 mL) and a solution
of 13 (198 mg, 1 mmol) in DMF (2 mL) were combined in a dry
Radleys reaction tube containing K2CO3 (166 mg, 1.2 mmol). The
reaction mixture was allowed to stir at 45 C overnight in a Radleys
parallel synthesizer. The reaction mixture was poured on crushed
ice (50 mL) and allowed to stand for few hours. The precipitate
formed was collected by ﬁltration, washed with H2O and lyophi-
lized, followed by recrystallization from EtOH. Pure 62 was
obtained as a white powder (208 mg, 58%). m/z (ES), found
356.9220 (C18H21N4O2S [M+H]+) requires 357.1307; dH/ppm
(400 MHz, d6-DMSO): 10.12 (1H, s, NH), 7.63 (1H, dd, J = 0.8 + 1.8,
Ar-H), 7.32 (1H, d, J = 1.7, Ar-H), 7.26 (1H, dd, J = 2.0 + 8.1, Ar-H),
7.05 (1H, d, J = 8.2, Ar-H), 6.49 (1H, dd, J = 0.6 + 3.2, Ar-H), 6.44
(1H, dd, J = 1.8 + 3.2, Ar-H), 5.21 (2H, s, CH2), 4.04 (2H, s, CH2),
2.40 (3H, s, CH3), 2.18 (3H, s, CH3), 2.16 (3H, s, CH3).
4.5.66. N-(3,4-Dimethyl-phenyl)-3-(4-furan-2-ylmethyl-5-
methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propionamide (63)
Procedure as for 1a except using 26 (423 mg, 2 mmol). The pre-
cipitate formed was collected, washed with H2O and lyophilized,
followed by recrystallization from EtOH. Pure 63 was obtained as
a white powder (89 mg, 12%). m/z (ES), found 369.1425 (C19H21N4-
O2S [MH]) requires 369.1463; dH/ppm (400 MHz, d6-DMSO):
9.85 (1H, s, NH), 7.62 (1H, dd, J = 0.8 + 1.7, Ar-H), 7.34 (1H, d,
J = 1.6, Ar-H), 7.27 (1H, dd, J = 2.0 + 8.1, Ar-H), 7.03 (1H, d, J = 8.2,
Ar-H), 6.46–6.42 (2H, m, Ar-H), 5.26 (2H, s, CH2), 4.32 (2H, t,
J = 7.3/7.4, CH2), 2.80 (2H, t, J = 7.3/7.4, CH2), 2.36 (3H, s, CH3),
2.17 (3H, s, CH3), 2.15 (3H, s, CH3).
4.5.67. 2-(4-Furan-2-ylmethyl-5-methyl-4H-[1,2,4]triazol-3-
ylsulfanyl)-N-(4-isopropyl-phenyl)-acetamide (64)
Procedure as for 1a except using 19 (212 mg, 1 mmol). The pre-
cipitate formed was collected, washed with H2O and lyophilized,
followed by recrystallization from EtOH. Pure 64 was obtained as
a white powder (181 mg, 49%). m/z (ES), found 370.9268 (C19H23-
N4O2S [M+H]+) requires 371.1463; dH/ppm (400 MHz, d6-DMSO):
10.21 (1H, s, NH), 7.63 (1H, dd, J = 0.7 + 1.8, Ar-H), 7.45 (2H, d,
J = 8.5, Ar-H), 7.17 (2H, d, J = 8.5, Ar-H), 6.48 (1H, d, J = 3.2, Ar-H),
6.44 (1H, dd, J = 1.8 + 3.2, Ar-H), 5.21 (2H, s, CH2), 4.05 (2H, s,
CH2), 2.83 (1H, hept, CH of isopropyl), 2.40 (3H, s, CH3), 1.17 [6H,
d, J = 6.9, (CH3)2].
4.5.68. 2-(4-Allyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-N-(4-
isopropyl-phenyl)-acetamide (65)
Procedure as for 1a except using 59 (155 mg, 1 mmol) and 19
(212 mg, 1 mmol). The precipitate formed was collected, washed
with H2O and lyophilized, followed by recrystallization from EtOH.
Product 65 was obtained as a white powder (143 mg, 43%). m/z
(ES), found 330.9950 (C17H23N4OS [M+H]+) requires 331.1514;
dH/ppm (400 MHz, d6-DMSO): 10.19 (1H, s, NH), 7.44 (2H, d,
J = 8.5, Ar-H), 7.17 (2H, d, J = 8.5, Ar-H), 6.00–5.85 (1H, m, CH of
allyl), 5.19 [1H, dd, J = 1.1 + 10.4, N-CH2 (Ha)], 4.88 [1H, dd,
J = 1.1 + 17.2, N-CH2 (Hb)], 4.59 (2H, d, J = 5.0, @CH2), 4.02 (2H, s,
CH2), 2.83 (1H, hept, CH of isopropyl), 2.31 (3H, s, CH3), 1.17 [6H,
d, J = 6.9, (CH3)2].
4.5.69. N-(4-Isopropyl-phenyl)-2-[4-(3-methoxy-propyl)-5-
methyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide (66)
Similar to 62 except using 60 (187 mg, 1 mmol) and 19 (212 mg,
1 mmol). The precipitate formed was collected, washed with H2O
and lyophilized. Puriﬁcation of the dried product by FCC
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(120 mg, 33%). m/z (ES), found 362.9810 (C18H27N4O2S [M+H]+)
requires 363.1776; dH/ppm (400 MHz, d6-DMSO): 10.21 (1H, s,
NH), 7.45 (2H, d, J = 8.5, Ar-H), 7.17 (2H, d, J = 8.5, Ar-H), 4.05
(2H, s, CH2), 3.95 (2H, t, J = 7.2/7.3, CH2-OCH3), 3.28 (2H, t, J = 5.8,
N-CH2), 3.22 (3H, s, OCH3), 2.83 (1H, hept, CH of isopropyl), 2.34
(3H, s, CH3), 1.91–1.82 (2H, m, CH2), 1.17 [6H, d, J = 6.9, (CH3)2].
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